Interleukin (IL)-20 is a proinflammatory cytokine involved in rheumatoid arthritis, atherosclerosis, and osteoporosis. However, the role of IL-20 in hepatocellular carcinoma (HCC) is unclear. We explored the function of IL-20 in HCC. Tumor tissue samples were analyzed the expression of IL-20 and cyclin D1 by using immunohistochemistry staining and quantitative real-time polymerase chain reaction (qRT-PCR) analysis. To examine the role of anti-IL-20 monoclonal antibody (7E) in tumor growth, BALB/c mice was injected with ML-1 cells and treated with 7E. HCC tumor tissue expressed higher levels of IL-20 than did non-tumor tissue. High IL-20 expression in HCC was correlated with poor overall survival (relative risk:>3). IL-20 and cyclin D1 expression were also highly correlated in HCC patient specimens and 3 human HCC cell lines. IL-20 also increased cell proliferation and migration, and it regulated matrix metalloproteinase (MMP)-13, tumor necrosis factor (TNF)-α, cyclin D1, and p21 WAF1 expression in ML-1 cells. 7E attenuated tumor growth in mice inoculated with ML-1 cells. The expression of cyclin D1, TNFα, MMP-9, and vascular endothelial growth factor was significantly inhibited after 7E treatment. The findings of this study suggest that IL-20 plays a role in the tumor progression of HCC.
IL-20 is well known as an inflammatory cytokine involved in many immune diseases and tumorigenesis. We recently reported 10 that IL-20 promotes tumor progression and affects clinical outcome in breast cancer. We also found that anti-IL-20 monoclonal antibody (mAb) 7E alleviates inflammation in oral cancer and suppresses tumor growth 11 . The role of IL-20 in HCC is still unclear. In this study, we investigated whether IL-20 is involved in the pathogenesis of HCC and analyzed the mechanism of IL-20 in HCC. We also explored whether 7E inhibits tumor growth in a murine model of HCC.
Results

IL-20 expression in tumor tissue was correlated with clinical outcome. One hundred and four
HCC samples were immunohistochemistry stained with 7E and yielded 52 cases of high and 52 cases of low IL-20 expression ( Fig. 1a ). Higher IL-20 expression was significantly related to the Child-Pugh Classification (P = 0.010), tumor multiplicity (P = 0.003), tumor differentiation (P = 0.003), the primary tumor (P = 0.002), the American Joint Committee on Cancer TNM system stage (P = 0.002), the CLIP score (P = 0.001), and the Okuda stage (P = 0.003) ( Table 1 ). In addition, univariate survival analysis showed that IL-20 expression was highly correlated with poor local recurrence-free survival (P < 0.0001, Fig. 1b ) and poor overall survival (P < 0.0001, Fig. 1c ) ( Table 2 ). In multivariate survival analysis, high IL-20 expression was also correlated with poor overall survival (RR = 3.025, 95% CI = 1.110-8.241, P = 0.030) and poor local recurrence-free survival (RR = 2.348, 95% CI = 1.211-4.553, P = 0.011) ( Table 3 ). mRNA expression in HCC tumor tissue was significantly higher than non-HCC tissue in 26 patients (Fig. 1d) . The upregulated IL-20 and cyclin D1 mRNA expression in patient HCC tissues showed that the IL-20 mRNA expression was highly correlated with cyclin D1 expression (R = 0.658, P < 0.0010, Fig. 1e ). Both IL-20 and cyclin D1 mRNA were expressed in three different human hepatoma cell lines ( Fig. 1f ).
IL-20 expression was highly associated with cyclin D1 expression in HCC tumor tissue.
Cell migration and the expression of TNF-α and MMP-13 in IL-20-treated ML-1 cells.
Immunocytochemical staining and RT-PCR showed that IL-20 and its three receptors-IL-20R1, IL-20R2, and IL-22R1-were all expressed in ML-1 cells and Huh-7 cells (Supplementary Figs S1a and S3a). A Boyden chamber assay ( Supplementary Fig. S1b ,c) and a real-time migration assay ( Fig. 2a,b and Supplementary Fig. S3b ) both showed that migration was significantly higher in ML-1 cells and Huh-7 treated with IL-20, the activity was significantly inhibited in those after co-treated with 7E.
We used qRT-PCR to determine the targets directly affected by IL-20; TNF-α, and MMP mRNA expression. We explored the association of IL-20 expression with inflammatory cytokines in HCC tumor formation. TNF-α expression was higher in IL-20-treated ML-1 and Huh-7 cells than in 7E-treated cells ( Fig. 2c and Supplementary  Fig. S3e ). MMP-2, -8, or -12 expression was not significantly changed in ML-1 and Huh-7 cells after IL-20 treatment (data not shown); however MMP-13 expression was significantly upregulated by IL-20, which was inhibited by 7E in ML-1 cells (Fig. 2d ). MMP-9 was significantly upregulated by IL-20, which was inhibited by 7E in Huh-7 Supplementary Fig. S3f ). These results indicated that IL-20 is an important regulator of tumor progression in HCC.
Cell proliferation and cyclin D1 expression were inhibited in 7E-treated ML-1 cells. A MTT assay
showed that proliferation was inhibited in 7E-treated (2 μg/ml) ML-1 cells ( Fig. 3a ). Flow cytometry revealed that the percentage of ML-1 cells in the G1 phase was 6% higher after 7E treatment (2 μg/ml); this increase was associated with a concomitant decrease of cells in the G2-M phases of the cell cycle ( Fig. 3b ).
Because of the G1 arrest in the cell cycle of 7E-treated ML-1 cells, we used qRT-PCR ( Fig. 3c ) and immunoblotting ( Fig. 3d ) to analyze the levels of cyclin D1 in those cells. The transcription and protein levels of cyclin D1 were lower, and the p21 WAF1 protein level was higher in 7E-treated ML-1 cells.
Furthermore, we examined if higher dose of IL-20 regulates the proliferation in ML-1 and Huh-7 cells. A MTT assay showed that the proliferation of ML-1 and Huh-7 cells were higher after the cells had been treated with 400 ng/ml and 1000 ng/ml of IL-20, and that proliferation was inhibited in cells that had been treated with 7E ( Supplementary Figs S2a, S3c ). Cyclin D1 mRNA expression in ML-1 and Huh-7 cells were also higher after the cells had been treated with 400 ng/ml and 1000 ng/ml of IL-20, and inhibited in cells that had been treated with 7E (Supplementary Figs S2b and S3d). Tumor growth in vivo was lower in 7E-treated mice. IL-20 was highly expressed in human HCC tumor tissue, and cell migration was significantly higher in ML-1 cells treated with IL-20. Because migration and proliferation are inhibited in cells treated with 7E, we analyzed tumor growth in vivo in BALB/c mice. ML-1 cells were injected into the left fat pads of the mice. They were then injected (s.c.) with PBS, mIgG, or 7E twice per week for the next 25 days. Tumors were smaller and weight was lower in the 7E-treated group than in the mIgGand PBS-treated groups (Fig. 4A,B and Supplementary Fig. S4 ). qRT-PCR showed that cyclin D1, TNF-α, VEGF, and MMP-9 mRNA expression were significantly lower in the 7E-treated group than in the mIgG-treated group ( Fig. 4C-F) . The results demonstrated that IL-20 is involved in the pathogenesis of HCC and 7E significantly inhibited tumor growth.
Discussion
In this study, we found that IL-20 was critical in HCC. In clinical specimens, IL-20 was highly expressed in HCC tumor tissue. IL-20 expression in HCC patients was correlated with liver cirrhosis, tumor multiplicity and differentiation, and tumor stages. High IL-20 expression in HCC also correlated with poor overall survival (RR > 3). Moreover, IL-20 was positively correlated with cyclin D1 expression in patients with HCC and in human HCC cell lines. In in vitro assays, IL-20 increased cell proliferation and migration, and it upregulated cyclin D1, MMP-13, and TNF-α expression in the mouse ML-1 HCC cell line. In in vivo assays, the anti-IL-20 mAb 7E attenuated tumor growth in mice injected with ML-1 cells. These indicate that IL-20 is important in the progression of HCC. Chronic inflammation is frequently linked to the development of cancer. The inflammatory cells and cytokines found in tumors are likely to contribute to tumor growth, progression, and immunosuppression 12 . Multiple risk factors, such as HBV and HCV infections and alcohol-induced chronic inflammation are involved in the development of HCC 13 . Blockading cytokines and chemokines and treatment with nonsteroidal anti-inflammatory drugs reduces the incidence of tumors 12 . Many inflammatory cytokines, such as TNF-α, IL-1, and IL-6 are associated with HCC 3, 14, 15 . The role of IL-20, as an inflammatory cytokine, in HCC has never been investigated. In this study, IL-20 was highly expressed in HCC tumor tissue and correlated with tumor stages and overall survival. Therefore, IL-20 is important in the pathogenesis of HCC.
Cyclin D1 is well known as an important regulator of cell proliferation and enhancer of several processes relevant to malignant cell transformation, including abnormal growth, angiogenesis, and resistance to apoptosis 16 . Cyclin D1 is overexpressed in human HCC 17 ; thus, it is important in human HCC 5 . We found that IL-20 was associated with cyclin D1 mRNA expression in patients with HCC and three human HCC cell lines, which indicates that IL-20 was involved in tumor growth in HCC. Both the proliferation assay in vitro and tumor growth assay in vivo showed that 7E inhibited cyclin D1-mediated tumor growth, which indicates that IL-20 has an important regulatory role in HCC progression through cyclin D1. The highly correlated expression between IL-20 and cyclin D1 also suggests that IL-20 might be a predictive marker of HCC tumor growth.
We also found that inhibiting tumor cell proliferation using 7E was associated with the arrest of the cell cycle in the G0/G1 phases in vitro. Within 24 h after 7E had been added to the cell culture, cyclin D1 protein expression significantly fell and cell cycle inhibitor protein p21 WAF1 expression significantly rose. The increased p21 WAF1 expression inhibited cyclin D1/CDK4 complex activity, which explains cell cycle arrest in the G1 phase, and the cell cycle arrest contributed to the 7E-induced inhibition of tumor growth.
However, there were no significant changes in cell proliferation and cyclin D1 expression in ML-1 cells treated with IL-20 (200 ng/ml). This might be attributable to endogenous IL-20 expression in ML-1 cells. Therefore, we used a higher dose of IL-20 (1000 ng/ml). We found that the higher dose of IL-20 (1000 ng/ml) increased cell proliferation. In addition, the higher dose of IL-20 (400 ng/ml and 1000 ng/ml) increased cyclin D1 mRNA expression. Because ML-1 cells already endogenously expressed a high level of IL-20, a much higher dose of exogenous IL-20 was required to observe its effect on cell proliferation. TNF-α is a major mediator of inflammation. It may act as a tumor promoter by contributing to the tissue remodeling and stromal development necessary for tumor growth and metastasis 18 . TNF-α can induce protease production and vascularization for invasion in tumor cells 12 . We found that IL-20 expression was highly associated with HCC tumor stages in our clinical specimens. IL-20 regulated cell migration and upregulated TNF-α and MMP-13 expression in ML-1 cells. In the mouse model for tumor growth, 7E inhibited both TNF-α expression and tumor growth. Moreover, 7E inhibited MMP-9 and VEGF expression in tumors. This is consistent with our previous finding that IL-20 directly and indirectly induces angiogenesis by regulating VEGF 19 . The matrix metalloproteinases (MMPs) have been shown to be critical modulators of ECM composition and are thus crucial in neoplastic cell invasion and metastasis. Our results demonstrated that IL-20 is involved in many phases of tumor progression: tumor proliferation, migration, and angiogenesis. In addition, IL-20 provides a favorable microenvironment by upregulating proinflammatory cytokines. Therefore, IL-20 produced by cancer cells promotes tumor progression not only by its direct autocrine effect, but also by nurturing a microenvironment for tumor growth and metastasis. 7E inhibited all of these activities in vitro and in vivo and potently reduced tumor development in HCC. Therefore, we conclude that IL-20 is pivotal in HCC tumor progression. IL-20 might be a useful predictive marker for HCC progression and anti-IL-20 monoclonal antibody 7E has therapeutic potential in HCC. 
Expression and purification of human and mouse IL-20 recombinant protein. The human IL-20
fragment from Leu 25 to Glu 176 and mouse IL-20 fragment from Leu 25 to Leu 176 was amplified using PCR and inserted into the mammalian expression vector, pSecTag2A (Invitrogen, Carlsbad, Calif.). A Tag consisting of six histidine residues was placed at the C-terminus of the recombinant proteins. The protein was expressed in 293T cells and purified using metal affinity chromatography, as previously described 19, 20 . The purity of the eluted fractions from the affinity column was checked by the SDS-PAGE test in a reducing condition according to the standard protocol. The purity of human and mouse IL-20 proteins was about 95%.
Reverse transcription (RT-PCR).
The total RNA of cells and tumor tissue was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) and underwent reverse transcription according to the manufacturer's instructions. The expression of mRNA was analyzed using amplified PCR and real-time PCR with gene-specific primers. GAPDH was as an internal control.
Quantitative real-time polymerase chain reaction (qRT-PCR).
Total RNA was isolated. Reverse transcription (RT) was done with reverse transcriptase (Thermo Scientific, Rockford, IL). The mRNA expression was then amplified on a thermocycler (LightCycler 480; Roche Diagnostics, Indianapolis, IN), with SYBR Green I (Roche Diagnostics) as the interaction agent. The quantitative analysis of mRNA was normalized with GAPDH as the housekeeping gene. Relative multiples of changes in mRNA expression were determined by calculating 2 −ΔΔCt . Primer sequence is listed in Supplementary Table 2 .
Immunohistochemistry staining. Paraffin-embedded-tissue samples were used for immunohistochemistry staining with purified 7E (2 μg/ml) at 4 °C overnight 21, 22 . Incubating paraffin tissue sections with mouse IgG isotype (R&D Systems, Minneapolis, MN) instead of primary antibody was the negative control. Two investigators trained in liver pathology and blinded to the sample sources analyzed the histology and the IL-20 expression levels of at least five sections from each patient. The scoring of immunohistochemistry stains in each specimen was determined using a histological score (H) 23 that was calculated using the following equation: H = ΣPi (i + 1), where i is the staining intensity of the stained tumor cells (0-3+), and Pi is the percentage (range: 0-100%) of stained tumor cells for each intensity. The IL-20 immunostaining was labeled low-grade (H < medium) or high-grade (H ≥ medium).
Cell culture. The murine HCC cell line ML-1 and human HCC cell line Huh-7 was purchased from The Food
Industry Research and Development Institute (Hsinchu, Taiwan). Cells were grown in Dulbecco's modified Eagle's minimal essential medium (DMEM) (Hyclone, Logan, UT) supplemented with 10% (v/v) FBS (Hyclone), 100 U/ ml of penicillin, and 100 mg/ml of streptomycin (Hyclone) and kept at 37 °C in a 5% CO2/95% air atmosphere.
Immunocytochemical staining. ML-1 and Huh-7 cells were fixed in 3.7% paraformaldehyde and then permeabilized using PBS with 0.1% Triton X-100. The cells were blocked by immersing them in antibody diluent with background reducing components (Dakocytomation, Carpinteria, CA) and then incubated with primary antibody in blocking reagent. Immunocytochemical analysis was done using a chromogen kit (Romulin AEC Chromogen Kit; Biocare Medical, Walnut Creek, CA) and counterstained with Mayer's hematoxylin (J. T. Baker, Phillipsburg, NJ). The antibodies used were IL-20R1, IL-20R2, IL-22R1(R&D system), and mIgG isotype controls.
Migration assays. The migration assay was done using a Boyden chamber housing a polycarbonate filter with 8-μm pores (Nucleopore, Cabin John, MD). The upper wells were loaded with 10 4 ML-1 cells. The lower chambers were filled with conditioned medium. The cells were incubated for 16 h at 37 °C. Cells adhering to the lower side of the filter were fixed in 100% methanol and stained with Liu's staining (Tonyar Biotech, Tao-Yuan, Taiwan) for counting. The number of cells on the lower surface of the filter was determined microscopically by counting 3 randomly selected fields.
The migration assay was also done using a real-time migration assay. ML-1 and Huh-7 cells were seeded at 5 × 10 4 cells/per well in 3.5-cm dishes and allowed to attach for 24 h. The cells were then exposed to conditioned medium. Cell migration kinetics was recorded (JuLI Smart Fluorescent Cell Analyser; Montreal Biotech) for approximately 16 h. The result was then analyzed using ImageJ Software (http://imagej.nih.gov/ij/download.html).
Cell proliferation assay. ML-1 cells were plated at a density of 4000 cells/ in 48-well plate and incubated with IL-20 (200 ng/ml), 7E (2 μg/ml), or IL-20 (200 ng/ml) plus 7E (2 μg/ml) for 48-72 h. Cell proliferation was determined using an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay (Sigma-Aldrich, St. Louis, MO). After the cells had been incubated in conditioned medium for 48-72 h, 0.5 mg/mL of MTT was added to each well and incubated for 3 h. The supernatant was aspirated, and DMSO (Sigma-Aldrich) was added to dissolve the blue crystals. Absorbance was determined at 550 nm.
Flow cytometry. ML-1 cells were plated at a density of 10 5 cells/ml in 6-well plate. After they had been incubated with conditioned medium for 24 h, the cells were harvested by trypsinization, collected by centrifugation, and fixed with 70% ethanol overnight. After they had been washed three times with cold PBS, the cells were stained with 100 μg/ml of propidium iodide (PI) and 50 μg/ml of DNase-free RNase A (Sigma-Aldrich) for 10 min. A flow cytometer (FACScan; Becton Dickinson, Franklin Lakes, NJ) was used to evaluate their DNA fluorescence. The percentages of cells in the sub-G 0 /G 1 and G 2 /M phases were quantified using WinMDI 2.8 software.
Immunoblotting. Cells were stimulated with conditioned medium for 24 h. Immunoblotting used antibody specific for p21 (GeneTex International, Hsinchu, Taiwan) and Cyclin D1 (Cell Signaling, Beverly, MA). β-actin (GeneTex) was used as a loading control. Tumor growth mouse model. All animal experiments were done according to the protocols of the National Institutes of Health standards and guidelines for the care and use of experimental animals. The research procedures were approved by the Animal Ethics Committee of National Cheng Kung University (IACUC approval No: 105087). The methods were carried out in accordance with the approved guidelines. All efforts were made to minimize animal suffering and to reduce the number of animals used. Male 8-week-old BALB/c mice were used in all experiments. For the tumor growth mouse model, the left fat pad of each mouse was injected s.c. with 10 6 ML-1 cells. The mice were then randomly assigned to one of three groups (n = 5 in each group) and treated with PBS, 7E (6 mg/kg; s.c.), or mouse IgG (6 mg/kg; s.c.) twice per week for the duration of the experiment. Twenty-five days after the tumor cells had been injected, the mice were killed and the tumor tissue was harvested.
